CLINICAL_TRIALS trial_result · 2018-12-31

Clinical Trial Update: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis [Phase 3]

Phase 3 study of MCI-186 (edaravone) for amyotrophic lateral sclerosis has completed, and results were posted on 2018-12-31.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Tanabe Pharma Corporation | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: COMPLETED | Results posted: 2018-12-31